Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beijing Succeeder TechnologySHSE:688338 +2.99%88 Return-on-Tangible-Equity is 4.60% as of Mar. 2026, which is 42% below its 10-year median of 7.89. GuruFocus rates SHSE:688338 with a GF Score™ of 88/100 and a GF Value™ of ¥30.98 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 759 Medical Devices & Instruments companies, Beijing Succeeder Technology ranks better than 52.44% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Beijing Succeeder Technology's annualized net income for the quarter that ended in Mar. 2026 was ¥77.3 Mil. Beijing Succeeder Technology's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ¥1,678.7 Mil. Therefore, Beijing Succeeder Technology's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 4.60%.
The historical rank and industry rank for Beijing Succeeder Technology's Return-on-Tangible-Equity or its related term are showing as below:
SHSE:688338'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 5.19 Med: 7.89 Max: 33.62
Current: 5.19
During the past 10 years, Beijing Succeeder Technology's highest Return-on-Tangible-Equity was 33.62%. The lowest was 5.19%. And the median was 7.89%.
SHSE:688338's Return-on-Tangible-Equity is ranked better than 52.44% of 759
companies
in the Medical Devices & Instruments industry
Industry Median: 4.09
vs SHSE:688338: 5.19
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Beijing Succeeder Technology Return-on-Tangible-Equity Related Terms
Beijing Succeeder Technology Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688338 vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Beijing Succeeder Technology's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Succeeder Technology Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Beijing Succeeder Technology's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Beijing Succeeder Technology's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 4.60% mean?
Beijing Succeeder Technology (SHSE:688338) has a Return-on-Tangible-Equity of 4.60% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Beijing Succeeder Technology and its competitors. This is 42% below median its historical median of 7.89. Over the past decade, Beijing Succeeder Technology's Return-on-Tangible-Equity has ranged from 5.19 to 33.62. According to the industry distribution chart, Beijing Succeeder Technology ranks #361 out of 759 companies in the Medical Devices & Instruments industry, placing it in the top 47.6%.
Is Beijing Succeeder Technology's Return-on-Tangible-Equity too high?
Beijing Succeeder Technology's current Return-on-Tangible-Equity of 4.60% is 42% below median its 10-year median of 7.89. Over the past 10 years, this metric has ranged from a low of 5.19 to a high of 33.62. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.09. Beijing Succeeder Technology's value of 4.60% is 12.5% above this industry median. Based on the distribution chart, Beijing Succeeder Technology ranks #361 out of 759 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Beijing Succeeder Technology has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Succeeder Technology's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Beijing Succeeder Technology ranks #361 out of 759 companies for Return-on-Tangible-Equity. This puts Beijing Succeeder Technology in the upper half of its industry. The industry median Return-on-Tangible-Equity is 4.09. Beijing Succeeder Technology's value of 4.60% is 12.5% above this benchmark. Historically, Beijing Succeeder Technology's own Return-on-Tangible-Equity has ranged from 5.19 to 33.62 over the past decade. While the company's 10-year median is 7.89 vs. the industry median of 4.09, Beijing Succeeder Technology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.09, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beijing Succeeder Technology's current Return-on-Tangible-Equity of 4.60% is 12.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Beijing Succeeder Technology and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Succeeder Technology's current Return-on-Tangible-Equity is 4.60%, which is 42% below median its own 10-year median of 7.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Succeeder Technology stock overvalued right now?
Based on GuruFocus' analysis, Beijing Succeeder Technology (SHSE:688338) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥30.98, compared to a current price of ¥26.14 — trading 15.6% below its estimated fair value. The current Return-on-Tangible-Equity is 4.60%, which is 42% below median its 10-year median of 7.89 and 12.5% above the Medical Devices & Instruments industry median of 4.09. Beijing Succeeder Technology's overall GF Score™ is 88/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Beijing Succeeder Technology (SHSE:688338), the current Return-on-Tangible-Equity is 4.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Succeeder Technology (SHSE:688338) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Succeeder Technology stock appears to be undervalued.
The current stock price of ¥26.14 is trading 15.6% below its estimated GF Value™ of ¥30.98.
GuruFocus considers Beijing Succeeder Technology to be Modestly Undervalued.
Key valuation signals for SHSE:688338:
Return-on-Tangible-Equity: 4.60% (42% below median its 10-year median of 7.89)
GF Value™: ¥30.98 vs. price of ¥26.14 (15.6% below fair value)
Industry Position: 12.5% above the Medical Devices & Instruments median (#361 of 759)
No single metric tells the full story. See the SHSE:688338 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Succeeder Technology Inc is engaged in production and sales of detection instruments, reagents and consumables in the field of in vitro diagnosis of thrombosis and hemostasis. The company develops, manufactures and sells in-vitro diagnostic products including coagulation analyzers and reagents, blood rheology analyzers, ESR analyzers and platelet aggregation analyzers. Its product portfolio includes Fully Auto Coagulation Analyzer; Semi Auto Coagulation Analyzer; ESR Analyzer; Platelet Aggregation Analyzer; and Coagulation Reagents.
88GF Score
Get the complete analysis for SHSE:688338
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688338 has been successfully added to your 
